Compare HUDI & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUDI | AIMD |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 16.9M |
| IPO Year | 2021 | N/A |
| Metric | HUDI | AIMD |
|---|---|---|
| Price | $1.25 | $2.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.8K | ★ 43.8K |
| Earning Date | 08-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,566,370.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $1.06 | $1.78 |
| 52 Week High | $5.46 | $5.00 |
| Indicator | HUDI | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 45.20 |
| Support Level | $1.23 | $2.03 |
| Resistance Level | $1.34 | $2.56 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 60.47 | 78.21 |
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.